CA2334761C - Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes - Google Patents

Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes Download PDF

Info

Publication number
CA2334761C
CA2334761C CA002334761A CA2334761A CA2334761C CA 2334761 C CA2334761 C CA 2334761C CA 002334761 A CA002334761 A CA 002334761A CA 2334761 A CA2334761 A CA 2334761A CA 2334761 C CA2334761 C CA 2334761C
Authority
CA
Canada
Prior art keywords
hmb
composition
arginine
animal
glutamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002334761A
Other languages
English (en)
Other versions
CA2334761A1 (fr
Inventor
Steven L. Nissen
Naji M. Abumrad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation ISURF
Original Assignee
Iowa State University Research Foundation ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22292520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2334761(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State University Research Foundation ISURF filed Critical Iowa State University Research Foundation ISURF
Publication of CA2334761A1 publication Critical patent/CA2334761A1/fr
Application granted granted Critical
Publication of CA2334761C publication Critical patent/CA2334761C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition comprenant de l'acide beta -hydroxy- beta -méthylbutyrique (HMB) et au moins un amino-acide. La présente invention concerne également une méthode de traitement de la fonte musculaire d'un animal liée à la maladie, une méthode permettant de réduire le taux sérique des triglycérides d'un animal, une méthode de réduction de la charge virale sérique d'un animal, une méthode de redistribution des graisses dans un animal ayant une zone viscérale et un zone sous-cutanée, une méthode permettant d'accroître la masse maigre d'un animal sans réduction sensible de sa masse adipeuse, et une méthode permettant d'accroître le niveau de cholestérol HDL chez un animal. Toutes ces méthodes impliquent l'administration d'une composition comprenant de l'acide beta -hydroxy- beta -méthylbutyrique et au moins un amino-acide à l'animal.
CA002334761A 1998-06-23 1999-06-23 Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes Expired - Lifetime CA2334761C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/102,941 1998-06-23
US09/102,941 US6031000A (en) 1998-06-23 1998-06-23 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
PCT/US1999/014097 WO1999066917A2 (fr) 1998-06-23 1999-06-23 COMPOSITION COMPRENANT DE L'ACIDE β-HYDROXY-β-METHYLBUTYRIQUE ET AU MOINS UN AMINO-ACIDE, ET METHODES D'UTILISATION CORRESPONDANTES

Publications (2)

Publication Number Publication Date
CA2334761A1 CA2334761A1 (fr) 1999-12-29
CA2334761C true CA2334761C (fr) 2009-04-28

Family

ID=22292520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002334761A Expired - Lifetime CA2334761C (fr) 1998-06-23 1999-06-23 Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes

Country Status (12)

Country Link
US (1) US6031000A (fr)
EP (1) EP1089726B1 (fr)
JP (2) JP5064609B2 (fr)
AU (1) AU756353B2 (fr)
CA (1) CA2334761C (fr)
DE (1) DE69901396T2 (fr)
DK (1) DK1089726T3 (fr)
ES (1) ES2177293T3 (fr)
NO (2) NO329914B1 (fr)
NZ (1) NZ508395A (fr)
PL (1) PL195623B1 (fr)
WO (1) WO1999066917A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362350B2 (ja) * 1997-10-16 2003-01-07 味の素株式会社 反芻動物の肥育方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (fr) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions visant a prevenir et reduire les courbatures du lendemain
ATE508745T1 (de) * 2005-11-30 2011-05-15 Novartis Pharma Gmbh Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund
WO2007075605A2 (fr) * 2005-12-19 2007-07-05 Abbott Laboratories Procede d'utilisation de ?-hydroxy-?-methylbutyrate
US8324175B2 (en) * 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) * 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
ES2689700T3 (es) * 2008-12-09 2018-11-15 Metabolic Technologies, Inc. Intervención nutricional para mejorar la función y resistencia muscular
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
NZ594434A (en) * 2009-01-29 2014-11-28 Young Hee Ko Compositions and methods for the treatment of cancer
EP2289555A1 (fr) * 2009-08-24 2011-03-02 OrgaNext Research B.V. Procédé de traitement des faiblesses
ES2608483T3 (es) * 2009-12-18 2017-04-11 Metabolic Technologies, Inc. Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB)
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
JP5892948B2 (ja) 2010-01-29 2016-03-23 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ カルシウムｈｍｂを含む栄養エマルジョン
RU2012125878A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Асептически упакованные питательные жидкости, содержащие бета-гидрокси-бета-метилбутират (гмб)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CN108261547A (zh) 2011-07-15 2018-07-10 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
US9327001B2 (en) 2011-11-03 2016-05-03 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
EP2782588B1 (fr) * 2011-11-21 2020-04-15 Emmaus Medical, Inc. Procédés et compositions pour le traitement du diabète et de symptômes associés
JP2015503619A (ja) 2012-01-11 2015-02-02 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 糖尿病性潰瘍を治療する際に使用するための、ベータ−ヒドロキシ−ベータ−メチルブチレート、アルギニンおよびグルタミンの組合せ
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
EP3733171B1 (fr) 2012-09-10 2023-10-25 Metabolic Technologies, LLC Compositions contenant du hmb et de l' atp ainsi que leurs utilisation
WO2014047497A1 (fr) 2012-09-21 2014-03-27 Abbott Laboratories Compositions nutritionnelles comprenant le bêta-hydroxy-bêta-méthylbutyrate de calcium, une protéine et de faibles taux d'électrolytes
WO2014047493A1 (fr) * 2012-09-21 2014-03-27 Abbott Laboratories Compositions nutritionnelles comprenant le bêta-hydroxy-bêta-méthylbutyrate de calcium et une protéine
US9943517B2 (en) 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US9713598B2 (en) * 2013-03-14 2017-07-25 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
EP3110507B1 (fr) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions et procédés permettant la réduction ou la prévention de stéatose hépatique
WO2016196637A1 (fr) * 2015-06-01 2016-12-08 Metabolic Technologies, Inc. Compositions et procédés d'utilisation de bêta-hydroxy-bêta-méthylbutyrate (hmb) pour la diminution de la masse graisseuse
JP7114458B2 (ja) 2015-09-16 2022-08-08 メタボリック・テクノロジーズ，インコーポレーテッド 軟組織外傷からの回復を増強するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
JP6875288B2 (ja) * 2015-11-19 2021-05-19 協和発酵バイオ株式会社 ３−ヒドロキシイソ吉草酸の一価カチオン塩の結晶および該結晶の製造方法
MX2018008903A (es) 2016-01-21 2019-02-21 Metabolic Tech Inc COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
AU2017253109B2 (en) * 2016-04-19 2023-03-23 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
CN109476578A (zh) 2016-06-24 2019-03-15 协和发酵生化株式会社 3-羟基异戊酸氨基酸盐的晶体及其制造方法
EP3528801B1 (fr) 2016-10-21 2024-07-17 Metabolic Technologies, LLC Compositions et méthodes d'utilisation de beta-hydroxy-beta-méthylbutyrate (hmb) et de probiotiques
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
KR20200131810A (ko) * 2018-01-05 2020-11-24 텍사스 테크 유니버시티 오피스 오브 리서치 커머셜라이제이션 간헐적 금식과 관련된 β-하이드록시-β-메틸부티레이트 (HMB)의 조성물 및 사용 방법
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
NZ256300A (en) * 1992-09-16 1997-06-24 Univ Iowa State Res Found Inc Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
WO1994017678A1 (fr) * 1993-02-11 1994-08-18 Iowa State University Research Foundation, Inc. Procede d'augmentation de la valeur nutritive du colostrum et du premier lait de femelles porteuses de mammiferes
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE29707308U1 (de) * 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus

Also Published As

Publication number Publication date
NO20006633L (no) 2001-02-20
EP1089726B1 (fr) 2002-05-02
JP2002518440A (ja) 2002-06-25
WO1999066917A2 (fr) 1999-12-29
DE69901396D1 (de) 2002-06-06
AU4708099A (en) 2000-01-10
DK1089726T3 (da) 2002-07-22
NZ508395A (en) 2003-09-26
JP5064609B2 (ja) 2012-10-31
AU756353B2 (en) 2003-01-09
PL195623B1 (pl) 2007-10-31
DE69901396T2 (de) 2002-08-29
CA2334761A1 (fr) 1999-12-29
WO1999066917A3 (fr) 2000-04-20
ES2177293T3 (es) 2002-12-01
EP1089726A2 (fr) 2001-04-11
JP2012102118A (ja) 2012-05-31
US6031000A (en) 2000-02-29
JP5690261B2 (ja) 2015-03-25
PL344589A1 (en) 2001-11-05
NO20101440L (no) 2001-02-20
NO20006633D0 (no) 2000-12-22
NO329914B1 (no) 2011-01-24
NO332374B1 (no) 2012-09-10

Similar Documents

Publication Publication Date Title
CA2334761C (fr) Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes
EP2512236B1 (fr) Procédé amélioré permettant d'administrer du bêta-hydroxy-bêta-méthylbutyrate (hmb)
AU664511B2 (en) Method of promoting nitrogen retention in humans
US5453282A (en) Dietary lipid digestion-absorption inhibitory agents and ingesta
RU2195934C2 (ru) Высокие дозы трипиколината хрома для лечения диабета второго типа
JP2008534599A (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
US5431925A (en) Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression
KR20050089857A (ko) 간암 발생 및 진행 억제제
EP0786993B1 (fr) Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et leur utilisation dans le traitement de troubles metaboliques et cardiovasculaires
JP3622985B2 (ja) マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法
JP3908513B2 (ja) 肝機能改善剤
KR100304312B1 (ko) 아연이보충된전립선추출물
MXPA00011686A (es) Composicion que comprende acido beta-hidroxi-beta-metilbutirico y al menos un aminoacido y metodos de uso
CN114177185B (zh) 一种用于降低胆固醇与预防心血管疾病的药物组合物
CA3218375A1 (fr) Composition pour augmenter la masse musculaire
WO1996011679A1 (fr) Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et procedes de traitement de troubles metaboliques et cardiovasculaires
JP2001316272A (ja) 高尿酸血症又は痛風の予防又は改善剤

Legal Events

Date Code Title Description
FZDC Discontinued application reinstated
EEER Examination request
MKEX Expiry

Effective date: 20190625